BR0312169A - Composto, composição farmacêutica, uso do composto, método para o tratamento de um sujeito afligido por uma condição patológica ou doença suscpetivel de redução por antagonismo de receptores muscarìnicos m3 e produto de combinação - Google Patents

Composto, composição farmacêutica, uso do composto, método para o tratamento de um sujeito afligido por uma condição patológica ou doença suscpetivel de redução por antagonismo de receptores muscarìnicos m3 e produto de combinação

Info

Publication number
BR0312169A
BR0312169A BR0312169-0A BR0312169A BR0312169A BR 0312169 A BR0312169 A BR 0312169A BR 0312169 A BR0312169 A BR 0312169A BR 0312169 A BR0312169 A BR 0312169A
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
pathological condition
treating
reduction
Prior art date
Application number
BR0312169-0A
Other languages
English (en)
Inventor
Maria Antonia Buil Albero
Maria Dolors Fernandez Forner
Maria Prat Quinones
Original Assignee
Almirall Prodesfarma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Prodesfarma Ag filed Critical Almirall Prodesfarma Ag
Publication of BR0312169A publication Critical patent/BR0312169A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, USO DO COMPOSTO, MéTODO PARA O TRATAMENTO DE UM SUJEITO AFLIGIDO POR UMA CONDIçãO PATOLóGICA OU DOENçA SUSCPETìVEL DE REDUçãO POR ANTAGONISMO DE RECEPTORES MUSCARìNICOS M3 E PRODUTO DE COMBINAçãO". A presente invenção refere-se a carbamatos de fórmula Ou sais farmaceuticamente aceitáveis da mesma, incluindo os sais de amónia quaternária de fórmula (II) Assim como processos para a preparação das mesmas, composições farmacêuticas que compreendem as mesmas e o uso das mesmas em terapia como antagonistas de receptores muscarínicos M3.
BR0312169-0A 2002-06-21 2003-06-18 Composto, composição farmacêutica, uso do composto, método para o tratamento de um sujeito afligido por uma condição patológica ou doença suscpetivel de redução por antagonismo de receptores muscarìnicos m3 e produto de combinação BR0312169A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200201439A ES2203327B1 (es) 2002-06-21 2002-06-21 Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
PCT/EP2003/006472 WO2004000840A2 (en) 2002-06-21 2003-06-18 Quinuclidine derivatives and pharmaceutical compositions containing the same

Publications (1)

Publication Number Publication Date
BR0312169A true BR0312169A (pt) 2005-03-29

Family

ID=29797397

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0312169-0A BR0312169A (pt) 2002-06-21 2003-06-18 Composto, composição farmacêutica, uso do composto, método para o tratamento de um sujeito afligido por uma condição patológica ou doença suscpetivel de redução por antagonismo de receptores muscarìnicos m3 e produto de combinação

Country Status (21)

Country Link
US (3) US7435742B2 (pt)
EP (1) EP1515968A2 (pt)
JP (1) JP2005533799A (pt)
CN (1) CN100363363C (pt)
AR (1) AR040275A1 (pt)
AU (1) AU2003279384A1 (pt)
BR (1) BR0312169A (pt)
CA (1) CA2490082A1 (pt)
EC (1) ECSP045484A (pt)
ES (1) ES2203327B1 (pt)
IL (1) IL165775A0 (pt)
MX (1) MXPA04012272A (pt)
NO (1) NO20050217L (pt)
NZ (1) NZ537252A (pt)
PE (1) PE20040579A1 (pt)
RU (1) RU2321588C2 (pt)
TW (1) TW200401776A (pt)
UA (1) UA85541C2 (pt)
UY (1) UY27850A1 (pt)
WO (1) WO2004000840A2 (pt)
ZA (1) ZA200410211B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ526580A (en) 2000-12-22 2005-04-29 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as M3 antagonists
ES2203327B1 (es) 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
DK2422786T3 (da) * 2004-04-22 2014-11-17 Boehringer Ingelheim Int Nye lægemiddelkombinationer til behandling af luftvejssygdomme
US20080287487A1 (en) * 2004-06-30 2008-11-20 Anthony William James Cooper Muscarinic Acetylcholine Receptor Antagonists
ES2246170B1 (es) * 2004-07-29 2007-04-01 Almirall Prodesfarma, S.A. Nuevo procedimiento para preparar derivados de carbamato de quinuclidinio.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
BRPI0614410A2 (pt) 2005-08-15 2011-03-29 Boehringer Ingelheim Int processo para preparação de betamiméticos
DE102006028286A1 (de) * 2006-06-20 2007-12-27 Wirsich, Konrad, Dipl.-Ing. (FH) Drehmoment- und rutschfest verbundene aus zwei Teilen bestehende Schaltzahnräder
EP1882691A1 (en) * 2006-07-26 2008-01-30 CHIESI FARMACEUTICI S.p.A. Quinuclidine derivatives as M3 antagonists
EP2119716A4 (en) * 2007-02-09 2011-06-01 Astellas Pharma Inc AZA BRIDGE CYCLE COMPOUND
CA2675942C (en) * 2007-02-23 2016-04-12 Theravance, Inc. Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists
EP2065385A1 (en) 2007-11-28 2009-06-03 Laboratorios SALVAT, S.A. Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester
EP2080507A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Pharmaceutical formulations comprising an anticholinergic drug
WO2011094434A2 (en) * 2010-01-28 2011-08-04 Theron Pharmaceuticals, Inc. 7-azoniabicyclo [2.2.1] heptane derivatives, methods of production, and pharmaceutical uses thereof
KR101987736B1 (ko) * 2011-03-18 2019-06-11 젠자임 코포레이션 글루코실세라마이드 합성효소 억제제
EP2631674A1 (de) * 2012-02-23 2013-08-28 ELMOS Semiconductor AG Verfahren und Sensorsystem zur Vermessung der Eigenschaften einer Übertragungsstrecke eines Messsystems zwischen Sender und Empfänger
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
JP6218940B2 (ja) * 2013-07-13 2017-10-25 ベイジン エフエスウェルカム テクノロジー ディベロップメント カンパニー リミテッド キニン系化合物、その光学異性体及びその製造方法と医薬用途
US10570127B1 (en) 2018-11-05 2020-02-25 Renexxion, Llc Material and methods for the treatment of gastro-intestinal disorders
CN114040762A (zh) 2019-02-04 2022-02-11 建新公司 使用葡糖神经酰胺合酶(gcs)的抑制剂治疗纤毛疾病
JP2023512366A (ja) 2020-02-03 2023-03-27 ジェンザイム・コーポレーション リソソーム蓄積性疾患と関連する神経学的症状を処置するための方法
CN115605202B (zh) 2020-03-26 2025-10-28 盐野义制药株式会社 具有血清素受体结合活性的芳香族杂环衍生物
AU2021311131B2 (en) 2020-07-24 2026-02-19 Genzyme Corporation Pharmaceutical compositions comprising venglustat
US20240083872A1 (en) * 2020-12-28 2024-03-14 Shionogi & Co., Ltd. Cyclic amine derivatives having serotonin receptor binding activity

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2762796A (en) * 1956-09-11 Iminodibenzyl derivative
GB1219606A (en) 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
GB1246606A (en) 1969-04-28 1971-09-15 Starogardzkie Zakl Farma Dibenzo-azepine derivatives
GB8825505D0 (en) * 1988-11-01 1988-12-07 Pfizer Ltd Therapeutic agents
GB8923590D0 (en) 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
GB9201751D0 (en) 1992-01-28 1992-03-11 Smithkline Beecham Plc Compounds
GB9202443D0 (en) 1992-02-05 1992-03-18 Fujisawa Pharmaceutical Co A novel substituted-acetamide compound and a process for the preparation thereof
WO1995006635A1 (en) * 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
AU685225B2 (en) 1994-02-10 1998-01-15 Yamanouchi Pharmaceutical Co., Ltd. Novel carbamate derivative and medicinal composition containing the same
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
ATE205490T1 (de) 1995-10-13 2001-09-15 Banyu Pharma Co Ltd Substituierte heteroaromatische derivate
AUPN862996A0 (en) 1996-03-13 1996-04-04 Fujisawa Pharmaceutical Co., Ltd. A novel substituted-acetamide compound
PE92198A1 (es) * 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
KR100751981B1 (ko) * 2000-06-27 2007-08-28 라보라토리오스 살바트, 에스.에이. 아릴알킬아민으로부터 유도된 카바메이트
NZ526580A (en) * 2000-12-22 2005-04-29 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as M3 antagonists
DE60121813T2 (de) 2000-12-28 2007-09-20 Almirall Ag Neue chinuclidinderivate und medizinische zusammensetzungen, die diese verbindungen enthalten
JP4505227B2 (ja) 2001-12-20 2010-07-21 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ １−アルキル−１−アゾニアビシクロ［２．２．２］オクタンカルバメート誘導体およびムスカリンレセプターアンタゴニストとしてのそれらの使用
ES2203327B1 (es) 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.

Also Published As

Publication number Publication date
RU2321588C2 (ru) 2008-04-10
CN1675206A (zh) 2005-09-28
CN100363363C (zh) 2008-01-23
NO20050217L (no) 2005-03-18
EP1515968A2 (en) 2005-03-23
US7435742B2 (en) 2008-10-14
RU2005101409A (ru) 2005-11-20
JP2005533799A (ja) 2005-11-10
UA85541C2 (ru) 2009-02-10
AU2003279384A1 (en) 2004-01-06
ES2203327B1 (es) 2005-06-16
US20090005412A1 (en) 2009-01-01
PE20040579A1 (es) 2004-09-08
WO2004000840A3 (en) 2004-02-19
IL165775A0 (en) 2006-01-15
ZA200410211B (en) 2005-09-06
ECSP045484A (es) 2005-01-28
CA2490082A1 (en) 2003-12-31
TW200401776A (en) 2004-02-01
AR040275A1 (es) 2005-03-23
ES2203327A1 (es) 2004-04-01
WO2004000840A2 (en) 2003-12-31
MXPA04012272A (es) 2005-04-08
US20090054480A1 (en) 2009-02-26
UY27850A1 (es) 2003-11-28
NZ537252A (en) 2006-07-28
US20060094751A1 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
BR0312169A (pt) Composto, composição farmacêutica, uso do composto, método para o tratamento de um sujeito afligido por uma condição patológica ou doença suscpetivel de redução por antagonismo de receptores muscarìnicos m3 e produto de combinação
BRPI0417820A (pt) heterociclos azabicìclicos como moduladores de receptor canabinóide
BRPI0509298A (pt) composto, composição farmacêutica, métodos de inibir receptor h3 de histamina em um mamìfero, para tratar ou prevenir um distúrbio do sistema nervoso, obesidade, e um distúrbio ou doença, e, uso de um composto
CY1109787T1 (el) Ανταγωνιστες υποδοχεα γλυκογονου, παρασκευη και θεραπευτικες χρησεις
BRPI0608436A2 (pt) derivados de n-(n-sulfonilaminometil) ciclopropanocarboxamida utilizáveis para o tratamento de dor
BRPI0417771A (pt) heterociclos azabicìclicos como moduladores de receptor canabinóides
BR0309167A (pt) Composto, processo para a produção de um composto, composição farmacêutica, uso do composto, método para o tratamento de um sujeito afetado por uma condição patológica ou doença e produto de combinação
CY1110922T1 (el) Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις
BR122018070508B8 (pt) derivados de arilamida triazol-substituída e seu uso
BRPI0508461B8 (pt) diaminopirimidinas, seus usos, e composição farmacêutica
IL184932A0 (en) Glucagon receptor antagonists, preperation and therapeutic uses
BRPI0519262A2 (pt) derivados de pirazol fundidos e mÉtodos de tratamento de distérbios metabàlicos-relacionados destes
BRPI0407097A (pt) Antagonista do casr
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
BRPI0517438A (pt) composto, método para tratar a condição associada com atividade de receptor muscarìnico m4, uso do composto, e, composição farmacêutica
ECSP088966A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
BR0308133A (pt) Forma polimórfica cristalina de cloridrato de irinotecan
BR0208405A (pt) Compostos de diidropirimina substituìdos com ciano e seu uso para tratar doenças
BRPI0507120A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização
BR0315346A (pt) Método para o tratamento ou prevenção de sintomas de vasomotores em um paciente, formulação farmacêutica e utilização de inibidor de re-apreensão de norepinefrina em combinação com antagonista de 5-h2a
ATE473961T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
BRPI0606502A2 (pt) compostos; processo para a fabricação de compostos; composições farmacêuticas; método para o tratamento ou prevenção de doenças que são associadas com a modulação de receptores h3; método para o tratamento ou prevenção de obesidade em um ser humano ou animal; método de tratamento ou prevenção de diabetes tipo ii em um ser humano ou animal e usos de compostos
BRPI0809873A2 (pt) "composto, processo para a preparação do composto, método para o tratamento de uma desordem do sistema nervoso central, composição farmacêutica, uso do composto, método para testar antagonistas e antagonistas com seletividade para o receptor 5-th6 e método de tratamento"
BR0105787A (pt) Composição farmacêutica, uso de um composto farmacêutico, método para tratamento de distúrbios, composto farmacêutico e método para confeccionar um composto farmacêutico
NO20080671L (no) Bisykliske piperaziner som metabotrofiske glutamatreseptorantagonister

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: ALMIRALL AG (CH)

Free format text: ALTERADO DE: ALMIRALL PRODESFARMA AG

B25A Requested transfer of rights approved

Owner name: LABORATORIOS ALMIRALL, S.A. (ES)

Free format text: TRANSFERIDO DE: ALMIRALL AG

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 7A. E 8A. ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 7A E 8A ANUIDADES.